William Gradishar, MD
Enriched profileBetsy Bramsen Professor of Breast Oncology; Professor of Medicine and Chief, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine · Northwestern University Feinberg School of Medicine
William Gradishar is Betsy Bramsen Professor of Breast Oncology; Professor of Medicine and Chief, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine at Northwestern University Feinberg School of Medicine. OpenAlex indexes 1,298 publications with 31,447 citations (h-index 80); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
William Gradishar, MD, is Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine (Division of Hematology and Oncology, Department of Medicine). The public record shows 1,298 publications with 31,447 citations (h-index 80), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 28 companies, 3 NIH-funded awards (1994–2006).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Breast Cancer Treatment Studies
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 28 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 265.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Member
FDA Oncologic Drugs Advisory Committee (ODAC) -- voting member at multiple 2023-2025 breast/prostate cancer drug review meetings
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologynewscentral.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Industry payments
Updated 13 Oct 2026
28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202513 payments$18,062openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202515 payments$15,851openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.9%HER2/neu Receptor Antagonist48.7%Fam-trastuzumab deruxtecan-nxki100%Part B, office-administered≥17 patientsEstrogen Receptor Antagonist3%Fulvestrant99%Orserdu1%Part D + Part B<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
26%Other antiemetics23.9%Fosaprepitant100%Part B, office-administered≥27 patientsSerotonin-3 Receptor Antagonist2.2%Palonosetron hcl100%Part B, office-administered≥36 patientsMusculoskeletal
18.2%RANK Ligand Inhibitor18.2%Denosumab100%Part B, office-administered≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
3 NIH research awards on record, funded 1994–2006 per NIH RePORTER. The latest:
- NCI 00B9: PHASE I/II TRIAL OF IN VIVO ANGIOSTATIN GENERATION IN BREAST CA
Northwestern University at Chicago
FY2006$11,404M01RR000048 - NCI 00B9: PHASE I/II TRIAL OF ANGIOSTATIN GENERATION IN BREAST CANCER
Northwestern University
FY2005$113,278M01RR000048
Congress activity
Updated 13 Oct 2026
183 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1967: Plexin-B2 mediates tumor cell clustering with monocyte interactions in breast cancer metastasis
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
Article2026 - Computational ranking identifies Plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis.
Nature communications
Article2025 - Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients.
JCO clinical cancer informatics
Article2025 - MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer.
Nature communications
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyArticle1,623 citations2020
- 03Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyArticle1,617 citations2018
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/william-gradishar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/william-gradishar-23816563
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/William-J-Gradishar-38427468
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/DrWGradishar
Mentions by others
where others cite or feature them- Other
onclive.com/view/marvels-in-medicine-dr-gradishar-on-the-personal-pursuit-of-precision-medicine-in-breast-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/LurieCancer/status/1987971087288688741
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board Certified
Internal Medicine, American Board of Internal Medicine
- Board Certified
Medical Oncology, American Board of Internal Medicine
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
- Chair
NCCN Guidelines Panel for Breast Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗ - Member
Breast Cancer Risk Reduction Panel (NCCN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗ - Deputy Director for the Clinical Network
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
- Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗ - Fellow
American Society of Clinical Oncology (FASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globalwomenshealthacademy.org ↗
Secondary affiliations
appointments beyond the home institution- Robert H. Lurie Comprehensive Cancer Center of Northwestern University -- member; Director
Maggie Daley Center for Women's Cancer Care
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →docwirenews.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University Feinberg School of Medicine
Martin Tallman, MD
Northwestern University Feinberg School of Medicine
Al Benson, MD
Northwestern University Feinberg School of Medicine
Sanjiv Shah, MD
Northwestern University Feinberg School of Medicine
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles